HLS Therapeutics Inc. (HLS.TO)
| Previous Close | 4.7500 |
| Open | 4.7500 |
| Bid | 4.6200 x 0 |
| Ask | 4.7500 x 0 |
| Day's Range | 4.7400 - 4.7500 |
| 52 Week Range | 3.3400 - 7.1200 |
| Volume | |
| Avg. Volume | 9,906 |
| Market Cap | 151.459M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1700 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | 0.20 (4.21%) |
| Ex-Dividend Date | Apr 27, 2023 |
| 1y Target Est | 6.70 |
- Baystreet
Stocks in play: HLS Therapeutics Inc.
Announces that Chief Executive Officer Craig Millian will present at the Bloom Burton & Co. Healthcare ...
CNW GroupHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place April 16-17, 2024 at the Metro Toronto Convention Centre, North Building, in downtown Toronto.
CNW GroupNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today highlighted two data presentations at the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular Events (MACE) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as r
